Related Experiment Video

Updated: Oct 17, 2025

Nasal Brushing Sampling and Processing Using Digital High Speed Ciliary Videomicroscopy – Adaptation for the COVID-19 Pandemic
09:03

Nasal Brushing Sampling and Processing Using Digital High Speed Ciliary Videomicroscopy – Adaptation for the COVID-19 Pandemic

Published on: November 7, 2020

5.1K

COVID-19 in Pediatrics

Siobhan Mary Case1, Mary Beth Son2

  • 1Division of Immunology, Boston Children's Hospital, 300 Longwood Avenue, Fegan, 6th Floor, Boston, Massachusetts 02115, USA; Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital, 60 Fenwood Road, 3rd Floor, Boston, MA 02115, USA.

Rheumatic Diseases Clinics of North America
|October 12, 2021
PubMed

Insights

This review covers diagnosing and treating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections, which cause coronavirus disease 2019 (COVID-19). It also addresses multisystem inflammatory syndrome in children (MIS-C), a new inflammatory condition following SARS-CoV-2 infection.

Area of Science:

  • Infectious Diseases
  • Pediatrics
  • Public Health

Background:

  • Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19).
  • Multisystem inflammatory syndrome in children (MIS-C) is a novel post-infectious condition.
  • Understanding these conditions is crucial for public health management.

Purpose of the Study:

  • To provide a comprehensive overview of SARS-CoV-2 infection diagnosis and treatment.
  • To review the current understanding of MIS-C, including its diagnosis and management.
  • To synthesize available information for healthcare professionals managing these pediatric and adult conditions.

Main Methods:

  • Literature review of diagnostic criteria for SARS-CoV-2 and MIS-C.
  • Analysis of current treatment guidelines for COVID-19.
  • Synthesis of epidemiological and clinical data on MIS-C.

Main Results:

  • Established diagnostic approaches for SARS-CoV-2 infection.
  • Detailed treatment strategies for COVID-19.
  • Characterization of MIS-C, including its clinical presentation and inflammatory markers.

Conclusions:

  • Effective diagnosis and management of SARS-CoV-2 are essential.
  • MIS-C requires prompt recognition and specific therapeutic interventions.
  • Continued research is needed to fully understand and combat these evolving health threats.

Keywords:
COVID-19CoronavirusMultisystem inflammatory syndrome in children (MIS-C)Pediatric inflammatory multisystem syndrome temporally related to SARS CoV-2 (PIMS-TS)

More Related Videos

Guidelines for Elective Pediatric Fiberoptic Intubation11:19

Guidelines for Elective Pediatric Fiberoptic Intubation

Published on: January 17, 2011

17.8K
Subcutaneous Infection of Methicillin Resistant Staphylococcus Aureus MRSA12:18

Subcutaneous Infection of Methicillin Resistant Staphylococcus Aureus MRSA

Published on: February 9, 2011

23.2K

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
35
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
36
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
31
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
34
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
43
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
502